(SVRA) Savara - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.066m USD | Total Return: 112.9% in 12m
Avg Turnover: 5.63M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Share dilution 17.2% YoY
Altman Z'' -4.07 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Savara Inc. (NASDAQ: SVRA) is a clinical-stage biotechnology company headquartered in Langhorne, Pennsylvania, specializing in the development of therapies for rare respiratory diseases. The firm’s primary focus is its lead candidate, molgramostim, an inhaled biologic currently in Phase 3 clinical trials for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
The biotechnology sector often utilizes an orphan drug business model, which provides regulatory incentives and extended market exclusivity for companies targeting rare conditions with high unmet medical needs. Developing inhaled biologics requires specialized delivery technology to ensure medication effectively reaches the deep lung tissue where respiratory diseases manifest.
Investors looking for deeper fundamental analysis of this clinical pipeline should consult ValueRay for additional data. Savara’s trajectory remains heavily dependent on the clinical outcomes and potential regulatory approval of molgramostim in the United States market.
- FDA approval of molgramostim nebulizer solution for autoimmune pulmonary alveolar proteinosis
- IMPALA-2 clinical trial results determine long-term commercial viability for lead candidate
- Orphan drug designation provides market exclusivity and premium pricing power potential
- Strategic partnerships or acquisition interest from larger biopharmaceutical respiratory players
- Cash runway and future capital raises impact clinical development timeline milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA -0.02 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.48 > 3% & CFO -106.9m > Net Income -129.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (253.3m) vs 12m ago 17.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.14%; Δ -0.14% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 209.3m - Total Current Liabilities 15.5m) / Total Assets 221.6m |
| B: -2.91 (Retained Earnings -645.4m / Total Assets 221.6m) |
| C: -0.65 (EBIT TTM -133.4m / Avg Total Assets 205.5m) |
| D: 3.86 (Book Value of Equity 176.0m / Total Liabilities 45.6m) |
| Altman-Z'' = -4.07 = D |
As of June 05, 2026, the stock is trading at USD 5.30 with a total of 989,300 shares traded.
Over the past week, the price has changed by +4.13%,
over one month by +0.00%,
over three months by -5.69% and
over the past year by +112.85%.
Savara has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SVRA.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10.8 | 104% |
P/E Forward = 0.4076
P/S = 145272.6216
P/B = 6.0591
Revenue TTM = 0.0 USD
EBIT TTM = -133.4m USD
EBITDA TTM = -133.2m USD
Long Term Debt = 30.1m USD (from longTermDebt, last quarter)
Short Term Debt = 7.00k USD (from shortTermDebt, last fiscal year)
Debt = 30.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 44.0k
Net Debt = -172.7m USD (calculated: Debt 30.1m - CCE 202.8m)
Enterprise Value = 893.0m USD (1.07b + Debt 30.1m - CCE 202.8m)
Interest Coverage Ratio = unknown (Ebit TTM -133.4m / Interest Expense TTM 0.0)
EV/FCF = -8.33x (Enterprise Value 893.0m / FCF TTM -107.2m)
FCF Yield = -12.00% (FCF TTM -107.2m / Enterprise Value 893.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 245k) / Revenue TTM)
Tobins Q-Ratio = 4.03 (Enterprise Value 893.0m / Total Assets 221.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 30.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -105.4m (EBIT -133.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.44 (Total Current Assets 209.3m / Total Current Liabilities 20.0m)
Debt / Equity = 0.17 (Debt 30.1m / totalStockholderEquity, last quarter 176.0m)
Debt / EBITDA = 1.30 (negative EBITDA) (Net Debt -172.7m / EBITDA -133.2m)
Debt / FCF = 1.61 (negative FCF - burning cash) (Net Debt -172.7m / FCF TTM -107.2m)
Total Stockholder Equity = 148.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.01% (Net Income -129.5m / Total Assets 221.6m)
RoE = -87.19% (Net Income TTM -129.5m / Total Stockholder Equity 148.5m)
RoCE = -74.71% (EBIT -133.4m / Capital Employed (Equity 148.5m + L.T.Debt 30.1m))
RoIC = -51.14% (negative operating profit) (NOPAT -105.4m / Invested Capital 206.1m)
WACC = 9.46% (E(1.07b)/V(1.10b) * Re(9.73%) + D(30.1m)/V(1.10b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 16.44%
[DCF] Fair Price = unknown (Cash Flow -107.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=-5.86% | Revisions=-20% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.15 | Chg30d=-62.11% | Revisions=-43% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.59 | Chg30d=-21.22% | Revisions=-43% | GrowthEPS=-11.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.36 | Chg30d=-11.20% | Revisions=-14% | GrowthEPS=+38.6% | GrowthRev=+2146.3%
[Analyst] Revisions Ratio: -43%